Organon & Co reported $8.49B in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Celltrion KRW 412.88B 1.61B Jun/2026
Cspc Pharmaceutical CNY 180.69M 21.94M Dec/2025
Deva Holding AS TRY 559.97M 44.39M Sep/2023
Dianthus Therapeutics USD 0 0 Dec/2024
Divis Laboratories Ltd INR 40M 10M Sep/2026
Gilead Sciences USD 23.82B 17M Sep/2026
Glaxosmithkline GBP 28.79B 10.26B Sep/2026
Kangmei Pharma CNY 67.35M 1.22M Jun/2026
Knight Therapeutics CAD 57.78M 26.92M Dec/2025
Laboratorios Farma EUR 80.5M 28.26M Dec/2024
Malin Corporation EUR 0 0 Dec/2024
Medical Developments International AUD 1.5M 167K Dec/2025
Merck USD 49.69B 1.39B Sep/2026
Novartis USD 36.7B 748M Sep/2026
Organigram Holdings CAD 17.61M 43.15M Jun/2026
Organon & Co USD 8.49B 6M Sep/2026
Ovoca Bio EUR 0 0 Jun/2021
Pharma Mar EUR 36.24M 4.11M Sep/2026
Qiagen NV USD 1.63B 19.45M Jun/2026
Sartorius EUR 3.43B 216.6M Sep/2026
Sino Biopharmaceutical CNY 3.08B 1B Jun/2025
Tilray USD 268.59M 3.82M Sep/2025
Zealand Pharma A/S 307M 76.14M Mar/2026